Regulus Therapeutics (RGLS) Tops Q4 EPS by 11c

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $5.09 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• KB Home (KBH) PT Raised to $56 at Truist Securities
• Ecolab pops as Citi sees improving setup into Q2 earnings